Connect your AI

Vaxcyte, Inc. PCVX Purchase Obligation

Purchase Obligation at other companies

ImmunityBio, Inc.IBRX

——

Other financials

Income statement

Operating income-$345.9M-91.3%

Net income-$320.6M-128%

EPS (diluted)-$2.30-121%

Balance sheet

Cash & equivalents$262.3M-24.7%

Total debt$116.3M+33.5%

Total equity$3.0B-6.4%

Total assets$3.3B-0.9%

Cash flow

Operating cash flow-$280.6M-68.8%

CapEx$2.1M-61.2%

Free cash flow-$282.7M-64.7%

Valuation

Market cap$7.43B+72.0%

Enterprise value$7.28B+78.6%

Returns & leverage

Return on equity-30.6%+37.9pp

Debt / equity0×0.0×

Current ratio7.5×-10.2×

Where this comes from

Reported directly by Vaxcyte, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OtherCommitment.

The official record: Vaxcyte, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Vaxcyte, Inc.'s purchase obligation.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Vaxcyte, Inc.'s purchase obligation?: Vaxcyte, Inc. (PCVX) reported purchase obligation of $722.64M in Q1 2026.
How has Vaxcyte, Inc.'s purchase obligation changed year-over-year?: Vaxcyte, Inc.'s purchase obligation increased by 91.1% year-over-year, from $378.2M to $722.64M.